Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity
- PMID: 25727178
- DOI: 10.1016/j.brachy.2015.01.002
Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity
Abstract
Purpose: Rates of late toxicity are higher for salvage treatment of local recurrence after prior radiotherapy. We present our experience with salvage prostate brachytherapy (BT) for local recurrence after definitive external beam radiotherapy with attention to the relationship between dose and late toxicity.
Methods and materials: From 2005 to 2012, 18 patients with biopsy proven locally recurrent prostate cancer and negative staging received low-dose-rate BT with a prescribed dose of 130-144 Gy. Toxicities were graded using Common Terminology Criteria for Adverse Events, version 3.0.
Results: Median followup is 31.5 months (range, 12-104). International Prostate Symptom Scores peaked at 3 months (median, 21/35), returning to baseline by 24 months. Urinary catheterization rate was 33% (median duration, 14 days; range, 1-90 days). Late Grade 3/4 genitourinary toxicity occurred in 1 patient each, one of whom also had Grade 3 late gastrointestinal toxicity; urethral strictures developed in three others. These 5 patients with late toxicity had higher dose to the prostate (isodose enclosing 90% [D90] median, 151 Gy; range, 135-185 Gy) compared with those without late complications (median, 134 Gy; range, 105-165; p < 0.04). Acute gastrointestinal toxicity Grade <3 occurred in 44%. Four patients (22%) experienced biochemical failure.
Conclusion: Salvage low-dose-rate prostate BT can provide durable biochemical control. Care should be taken to select patients with higher likelihood of organ-confined disease. The goal of planning should be to treat the recurrent disease to an adequate dose with careful attention to maintain a conservative D90.
Keywords: Adenocarcinoma; Low-dose-rate prostate brachytherapy; Prostate neoplasms; Radiation failures; Salvage brachytherapy.
Copyright © 2015 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.Brachytherapy. 2017 Jan-Feb;16(1):186-192. doi: 10.1016/j.brachy.2016.09.008. Epub 2016 Oct 27. Brachytherapy. 2017. PMID: 28341011
-
Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.Brachytherapy. 2016 Nov-Dec;15(6):722-729. doi: 10.1016/j.brachy.2016.08.004. Epub 2016 Sep 28. Brachytherapy. 2016. PMID: 27693225
-
Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.Radiat Oncol. 2017 Mar 9;12(1):49. doi: 10.1186/s13014-017-0789-9. Radiat Oncol. 2017. PMID: 28274241 Free PMC article.
-
High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy : A systematic review.Strahlenther Onkol. 2017 Sep;193(9):683-691. doi: 10.1007/s00066-017-1157-2. Epub 2017 Jun 16. Strahlenther Onkol. 2017. PMID: 28623436 English.
-
Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?Cancer Radiother. 2014 Oct;18(5-6):524-34. doi: 10.1016/j.canrad.2014.07.153. Epub 2014 Sep 2. Cancer Radiother. 2014. PMID: 25192626 Review.
Cited by
-
Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.J Contemp Brachytherapy. 2021 Feb;13(1):12-17. doi: 10.5114/jcb.2021.103581. Epub 2021 Feb 18. J Contemp Brachytherapy. 2021. PMID: 34025731 Free PMC article.
-
Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.Strahlenther Onkol. 2023 Jun;199(6):554-564. doi: 10.1007/s00066-023-02043-3. Epub 2023 Feb 2. Strahlenther Onkol. 2023. PMID: 36732443 Free PMC article.
-
Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma.Clin Transl Radiat Oncol. 2021 Jul 1;30:38-42. doi: 10.1016/j.ctro.2021.06.008. eCollection 2021 Sep. Clin Transl Radiat Oncol. 2021. PMID: 34307912 Free PMC article.
-
A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343. doi: 10.1016/j.ijrobp.2018.09.039. Epub 2018 Oct 9. Int J Radiat Oncol Biol Phys. 2019. PMID: 30312717 Free PMC article. Clinical Trial.
-
Comparative cost-effectiveness of focal and total salvage 125I brachytherapy for recurrent prostate cancer after primary radiotherapy.J Contemp Brachytherapy. 2016 Dec;8(6):484-491. doi: 10.5114/jcb.2016.64808. Epub 2016 Dec 27. J Contemp Brachytherapy. 2016. PMID: 28115953 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical